BACKGROUND: The aim of this study was to identify prognostic factors for local and systemic failure after isolated hepatic perfusion (IHP) with 200 mg melphalan in patients with colorectal liver metastases. PATIENTS AND METHODS: Hundred and fifty-four patients were selected for IHP and underwent laparotomy. Patients were monitored for response, toxicity and survival. Univariate and multivariate analyses were carried out to identify prognostic factors for hepatic response and progression-free and overall survival. RESULTS: Hepatic response rate was 50% with a median progression-free and overall survival of, respectively, 7.4 and 24.8 months. In multivariate analyses, absence of ability to perfuse through the hepatic artery (P = 0.003), severe postoperative complications (P = 0.048) and >10 liver metastases (P = 0.006) adversely influenced overall survival and no adjuvant chemotherapy adversely influenced progression-free survival. CONCLUSION: This is the first study to report prognostic factors for survival after IHP. Possibly, overall and disease-free survival can increase if preoperative screening is improved. In future studies on IHP, adjuvant chemotherapy should be considered.
BACKGROUND: The aim of this study was to identify prognostic factors for local and systemic failure after isolated hepatic perfusion (IHP) with 200 mg melphalan in patients with colorectal liver metastases. PATIENTS AND METHODS: Hundred and fifty-four patients were selected for IHP and underwent laparotomy. Patients were monitored for response, toxicity and survival. Univariate and multivariate analyses were carried out to identify prognostic factors for hepatic response and progression-free and overall survival. RESULTS: Hepatic response rate was 50% with a median progression-free and overall survival of, respectively, 7.4 and 24.8 months. In multivariate analyses, absence of ability to perfuse through the hepatic artery (P = 0.003), severe postoperative complications (P = 0.048) and >10 liver metastases (P = 0.006) adversely influenced overall survival and no adjuvant chemotherapy adversely influenced progression-free survival. CONCLUSION: This is the first study to report prognostic factors for survival after IHP. Possibly, overall and disease-free survival can increase if preoperative screening is improved. In future studies on IHP, adjuvant chemotherapy should be considered.
Authors: Geert Maleux; Diethard Monbaliu; Chris Verslype; Christophe Casteleyn; Marc Van De Velde; Pieter Cornillie; Yvonne Hoogeveen; Eric Van Cutsem Journal: Eur Radiol Date: 2010-05-22 Impact factor: 5.315
Authors: Martha M Kirstein; Steffen Marquardt; Nils Jedicke; Silke Marhenke; Wolfgang Koppert; Michael P Manns; Frank Wacker; Arndt Vogel Journal: J Cancer Res Clin Oncol Date: 2017-06-20 Impact factor: 4.553
Authors: Eleonora M de Leede; Mark C Burgmans; Christian H Martini; Fred G J Tijl; Arian R van Erkel; Jaap Vuyk; Ellen Kapiteijn; Cornelis Verhoef; Cornelis J H van de Velde; Alexander L Vahrmeijer Journal: J Vis Exp Date: 2016-07-31 Impact factor: 1.355
Authors: S C Bruin; Y He; I Mikolajewska-Hanclich; G-J Liefers; C Klijn; A Vincent; V J Verwaal; K A de Groot; H Morreau; M-L F van Velthuysen; R A E M Tollenaar; L J van 't Veer Journal: Br J Cancer Date: 2011-06-14 Impact factor: 7.640
Authors: Patricia Rusa Pereira; Alexandre Nakao Odashiro; Li-Anne Lim; Cristina Miyamoto; Paula L Blanco; Macanori Odashiro; Shawn Maloney; Dominique F De Souza; Miguel N Burnier Journal: Clin Ophthalmol Date: 2013-08-22
Authors: Fred M Moeslein; Elizabeth G McAndrew; William M Appling; Nicole E Hryniewich; Kevin D Jarvis; Steven M Markos; Timothy P Sheets; Rajneesh P Uzgare; Daniel S Johnston Journal: Cardiovasc Intervent Radiol Date: 2014-01-09 Impact factor: 2.740
Authors: Mark C Burgmans; Eleonora M de Leede; Christian H Martini; Ellen Kapiteijn; Alexander L Vahrmeijer; Arian R van Erkel Journal: Cardiovasc Intervent Radiol Date: 2015-12-30 Impact factor: 2.740